The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis
Open accessAbstract
BACKGROUND & AIMS: Eradication of Helicobacter pylori infection has been reported to reduce the risk of gastric cancer among asymptomatic individuals in high-risk areas. The magnitude of benefit of H pylori eradication in populations with different levels of gastric cancer risk and in different clinical scenarios is unclear. We performed a systematic review and meta-analysis of randomized controlled trials and observational studies to investigate the effects of H pylori eradication on the incidence of gastric cancer. METHODS: We searched PubMed, Cochrane Library, and ClinicalTrials.gov, reviewing titles and abstracts of studies of the effects of eradication of H pylori infection on risk of gastric cancer, through May 2015. We also searched bibliographies of included studies, related reviews, and abstracts presented at Digestive Disease Week. Twenty-four eligible studies (22 research manuscripts and 2 abstracts) were included in our meta-analysis (715 incident gastric cancers among a total of 48,064 individuals/340,255 person-years). We assessed the effects, as well as their modification by baseline gastric cancer incidence, study design (randomized trial vs observational study), clinical scenario (asymptomatic infected individuals vs individuals after endoscopic resection of early gastric cancer), demographic characteristics of patients (age and sex), and duration of follow-up. RESULTS: After adjustment for baseline gastric cancer incidence, individuals with eradication of H pylori infection had a lower incidence of gastric cancer than those who did not receive eradication therapy (pooled incidence rate ratio = 0.53; 95% confidence interval: 0.44-0.64). There was little heterogeneity among studies. Baseline gastric cancer incidence modified the benefit of H pylori eradication (P = .037 for interaction); the incidence rate ratio of gastric cancer decreased in a nonlinear fashion with increasing baseline incidence of gastric cancer (P = .018, in comparison with the linear model). The benefit also modestly increased with age (P = .023 for interaction), but this might be due to correlation between age and baseline gastric cancer incidence. Eradication provided significant benefit for asymptomatic infected individuals (pooled incidence rate ratio, 0.62; 95% CI: 0.49-0.79) and individuals after endoscopic resection of gastric cancers (pooled incidence rate ratio, 0.46; 95% CI: 0.35-0.60). The benefits of H pylori eradication did not differ with study design, sex, or follow-up period. CONCLUSIONS: In a systematic review and meta-analysis, we associated eradication of H pylori infection with a reduced incidence of gastric cancer. The benefits of eradication vary with baseline gastric cancer incidence, but apply to all levels of baseline risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We first conducted random-effects meta-analysis proposed by DerSimonian and Laird with the use of the incidence rate ratio as the measure of effect size.(18) Pre-planned subgroup meta-analyses were undertaken for studies of low, intermediate, and high baseline incidence of gastric cancer (defined by the tertiles of in…”
MethodPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Cited by
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312288 · Cited by 2,946
Self-citationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.563 · Cited by 1,604
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J. P., Liou, J.-M., Schulz, C., Gasbarrini, A., Hunt, R. H., Leja, M., O'Morain, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327745 · Cited by 1,533
Savoldi, A., Carrara, E., Graham, D. Y., Conti, M., & Tacconelli, E. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.007 · Cited by 1,270
Self-citationMalfertheiner, P., Camargo, M. C., El-Omar, E., Liou, J.-M., Peek, R., Schulz, C., Smith, S. I., & Suerbaum, S. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00431-8 · Cited by 1,191
Gastric cancer: a comprehensive review of current and future treatment strategies
Sexton, R. E., Al Hallak, M. N., Diab, M., & Azmi, A. S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09925-3 · Cited by 772
Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer
Choi, I. J., Kook, M.-C., Kim, Y.-I., Cho, S.-J., Lee, J. Y., Kim, C. G., Park, B., & Nam, B.-H. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708423 · Cited by 673
Banks, M., Graham, D., Jansen, M., Gotoda, T., Coda, S., di Pietro, M., Uedo, N., Bhandari, P., Pritchard, D. M., Kuipers, E. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-318126 · Cited by 647
Self-citationEtemadi, A., Safiri, S., Sepanlou, S. G., Ikuta, K., Bisignano, C., Shakeri, R., Amani, M., Fitzmaurice, C., Nixon, M., Abbasi, N., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30328-0 · Cited by 635
Liou, J.-M., Malfertheiner, P., Lee, Y.-C., Sheu, B.-S., Sugano, K., Cheng, H.-C., Yeoh, K.-G., Hsu, P.-I., Goh, K.-L., Mahachai, V., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-322368 · Cited by 493
Self-citationFord, A. C., Yuan, Y., & Moayyedi, P. (2020) · Gut · doi:10.1136/gutjnl-2020-320839 · Cited by 464
Cheung, K. S., Chan, E. W., Wong, A. Y. S., Chen, L., Wong, I. C. K., & Leung, W. K. (2018) · Gut · doi:10.1136/gutjnl-2017-314605 · Cited by 455
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
Chey, W. D., Howden, C. W., Moss, S. F., Morgan, D. R., Greer, K. B., Grover, S., & Shah, S. C. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002968 · Cited by 419
Role of microbiota-derived short-chain fatty acids in cancer development and prevention
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M. R., Hosseini-Fard, S. R., Babolhavaeji, K., Khani Ali Akbari, S., Yousefimashouf, R., & Karampoor, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111619 · Cited by 394
Matson, V., Chervin, C. S., & Gajewski, T. F. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.041 · Cited by 385
Changing Trends in Stomach Cancer Throughout the World
Balakrishnan, M., George, R., Sharma, A., & Graham, D. Y. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0575-8 · Cited by 384
Self-citationThe Clinical Evidence Linking Helicobacter pylori to Gastric Cancer
Moss, S. F. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.12.001 · Cited by 321
“meta-analyses of the many underpowered studies that were conducted are conclusive, indicating that H pylori eradication decreases the risk of gastric cancer development by approximately 40% in studies of primary prevention (asymptomatic individuals), and by 54% as a tertiary prevention strategy (preventing the occurre…”
ResultKuo, Y.-T., Liou, J.-M., El-Omar, E. M., Wu, J.-Y., Leow, A. H. R., Goh, K. L., Das, R., Lu, H., Lin, J.-T., Tu, Y.-K., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30219-4 · Cited by 319
Self-citationHuang, K. K., Ramnarayanan, K., Zhu, F., Srivastava, S., Xu, C., Tan, A. L. K., Lee, M., Tay, S., Das, K., Xing, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.018 · Cited by 294
Fallone, C. A., Moss, S. F., & Malfertheiner, P. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.04.011 · Cited by 286
Kumar, S., Metz, D. C., Ellenberg, S., Kaplan, D. E., & Goldberg, D. S. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.10.019 · Cited by 286
Updated epidemiology of gastrointestinal cancers in East Asia
Huang, J., Lucero-Prisno, D. E., Zhang, L., Xu, W., Wong, S. H., Ng, S. C., & Wong, M. C. S. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00726-3 · Cited by 269
Sung, J. J. Y., Coker, O. O., Chu, E., Szeto, C. H., Luk, S. T. Y., Lau, H. C. H., & Yu, J. (2020) · Gut · doi:10.1136/gutjnl-2019-319826 · Cited by 267
Jin, G., Lv, J., Yang, M., Wang, M., Zhu, M., Wang, T., Yan, C., Yu, C., Ding, Y., Li, G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30460-5 · Cited by 255
Cancer in Africa 2018: The role of infections
Parkin, D. M., Hämmerl, L., Ferlay, J., & Kantelhardt, E. J. (2020) · International Journal of Cancer · doi:10.1002/ijc.32538 · Cited by 130
Promising dawn in tumor microenvironment therapy: engineering oral bacteria
Wang, Z., Sun, W., Hua, R., Wang, Y., Li, Y., & Zhang, H. (2024) · International Journal of Oral Science · doi:10.1038/s41368-024-00282-3 · Cited by 97
Segna, D., Brusselaers, N., Glaus, D., Krupka, N., & Misselwitz, B. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211051463 · Cited by 56
Xu, J., Hu, S., Chen, Q., Shu, L., Wang, P., & Wang, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-41444-3 · Cited by 6
Metadata
- Authors
- Lee, Y.-C., Chiang, T.-H., Chou, C.-K., Tu, Y.-K., Liao, W.-C., Wu, M.-S., & Graham, D. Y.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 150
- Issue
- 5
- Pages
- 1113-1124.e5
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2254794399
- Cited by
- 1,013
- References
- 52
- FWCI
- 19.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.